サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1211054

T細胞リンパ腫の世界市場規模調査・予測：リンパ腫タイプ別、治療タイプ別、地域別分析、2022-2029年

Global T-Cell Lymphoma Market Size study & Forecast, by Lymphoma Type, Therapy Type and Regional Analysis, 2022-2029
出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.11円
T細胞リンパ腫の世界市場規模調査・予測：リンパ腫タイプ別、治療タイプ別、地域別分析、2022-2029年
出版日: 2023年01月25日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のT細胞リンパ腫市場は、2021年に約15億8,889万米ドルと評価され、予測期間2022-2029年には8.25％以上の健全な成長率で成長すると予想されています。

T細胞リンパ腫は、T細胞という免疫系で発生する血液がんの一種です。T細胞リンパ腫の市場は、リンパ腫がんの発生率の上昇、T細胞リンパ腫特異的治療法の進歩、自己免疫疾患によるリンパ腫のリスクなどの要因によって拡大しています。この市場は、ジョンソン・エンド・ジョンソン（ヤンセン・ファーマシューティカルズ・インク）、ノバルティスAG、ブリストル・マイヤーズスクイブ・カンパニー、メルク・アンド・カンパニー、F.ホフマン・ブラザーズ・インクが支配しています。Inc.、F. Hoffmann-La Roche Ltd.の5社です。

血液がんの増加により、T細胞リンパ腫の有病率が高まっています。白血病リンパ腫協会（R）（LLS）によると、米国では約3人に1人が白血病、リンパ腫、骨髄腫のいずれかと診断されています。2021年には、米国で合計186,400人が白血病、リンパ腫、骨髄腫と診断されると予想されています。2021年に米国で新たに診断されるがん患者数1,898,160人のうち、白血病、リンパ腫、骨髄腫の新規患者数は9.8％を占めると予想されます。さらに、プレミアム価格帯の製品や免疫チェックポイント阻害剤の取り込み、および市販製品のラベル延長に伴う複数の新規治療薬の上市により、今後数年間はこの市場の機会が増加すると予想されます。しかし、治療費の高さと治療薬の有害な副作用が、2022年から2029年の予測期間を通じて市場の成長を阻害しています。

世界のT細胞リンパ腫市場の調査において考慮された主要地域は、アジア太平洋、北米、欧州、中南米、その他の地域です。北米は、ブランド製品の優位性とこの地域の疾患有病率の増加により、収益面で市場を独占しています。Globocan 2020レポートによると、2020年にカナダで非ホジキンリンパ腫の患者が8,506人発生し、313人が死亡しています。これにより、同国におけるT細胞リンパ腫の発症率が上昇することが予想されます。アジア太平洋地域は、疾病の増加、免疫システムの弱さ、ネチズンの健康意識の高まり、市場空間における政府および非営利団体の積極的な参加などの要因により、予測期間中に最も高いCAGRで成長すると予想されます。

本調査の目的は、近年におけるさまざまなセグメントと国の市場規模を定義し、今後数年間の値を予測することです。本レポートは、調査対象国における産業の質的・量的な側面を取り込むように設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細な情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場の潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

  • 市場スナップショット
  • 世界・セグメント別市場推定・予測、2019年～2029年
    • T細胞リンパ腫市場：地域別、2019-2029年
    • T細胞リンパ腫市場（リンパ腫タイプ別）：2019-2029年
    • T細胞リンパ腫市場（治療法タイプ別）：2019-2029年
  • 主な動向
  • 調査手法
  • 調査前提条件

第2章 T細胞リンパ腫の世界市場定義と範囲

  • 調査の目的
  • 市場の定義と範囲
    • 調査対象範囲
    • 産業の進化
  • 調査対象年
  • 通貨換算レート

第3章 世界のT細胞リンパ腫市場力学

  • T細胞リンパ腫の市場インパクト分析（2019-2029年）
    • 市場促進要因
      • リンパ腫のがん罹患率の上昇
      • T細胞リンパ腫に特異的な治療法の進歩
      • 自己免疫疾患別リンパ腫のリスク
    • 市場の課題
      • 高い治療費
      • 治療薬の有害な副作用
    • 市場機会
      • 高価格帯の製品と免疫チェックポイント阻害剤の採用
      • いくつかの新規治療薬の上市と既存製品の適応拡大

第4章 世界のT細胞リンパ腫市場の産業分析

  • ポーターの5フォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターの5フォースモデルへの未来的アプローチ（2019-2029年）
  • PEST分析
    • 政治的
    • 経済的
    • 社会的
    • 技術的
  • トップ投資機会
  • 主要成功戦略
  • 業界専門家別展望
  • アナリストの結論・提言

第5章 リスク評価：COVID-19のインパクト

  • COVID-19が業界に与える全体的な影響の評価
  • COVID-19以前とCOVID-19以後の市場シナリオ

第6章 T細胞リンパ腫の世界市場、リンパ腫タイプ別

  • 市場スナップショット
  • T細胞リンパ腫の世界市場：リンパ腫タイプ別、業績-ポテンシャル分析
  • T細胞リンパ腫の世界市場、リンパ腫タイプ別推定・予測2019～2029年
  • T細胞リンパ腫の市場、サブセグメント分析
    • 末梢性T細胞性リンパ腫
    • T細胞リンパ芽球性リンパ腫

第7章：T細胞性リンパ腫の世界市場：治療タイプ別

  • 市場スナップショット
  • T細胞リンパ腫の世界市場：治療タイプ別、性能-潜在能力分析
  • T細胞リンパ腫の世界市場、治療タイプ別推定・予測2019-2029年
  • T細胞リンパ腫の市場、サブセグメント分析
    • 放射線療法
    • 化学療法
    • 免疫療法
    • 幹細胞移植
    • その他のタイプの治療法

第8章 T細胞リンパ腫の世界市場：地域別分析

  • T細胞リンパ腫の市場、地域別市場スナップショット
  • 北米
    • 米国
      • リンパ腫タイプ別の推定・予測、2019-2029年
      • 治療タイプ別の推定・予測、2019年～2029年
    • カナダ
  • 欧州T細胞リンパ腫市場スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他の欧州地域
  • アジア太平洋地域のT細胞リンパ腫市場のスナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカのT細胞リンパ腫市場スナップショット
    • ブラジル
    • メキシコ
    • その他のラテンアメリカ地域
  • 世界のその他の地域

第9章 競合情報

  • トップ市場戦略
  • 企業プロファイル
    • Genmab AS
      • 主要情報
      • 概要
      • 財務情報（データの入手状況により異なります）
      • 製品概要
      • 最近の動向
    • Johnson & Johnson（Janssen Pharmaceuticals Inc.）
    • Mundipharma International, Limited
    • Bristol-Myers Squibb Company
    • Autolus Therapeutics PLC
    • Acrotech Biopharma, Inc.
    • Macopharma
    • Merck & Co. Inc.
    • F. Hoffmann-La Roche Ltd
    • Novartis AG

第10章 調査プロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • バリデーション
    • 出版
  • 調査属性
  • 調査の前提条件
図表

LIST OF TABLES

  • TABLE 1. Global T-Cell Lymphoma Market, report scope
  • TABLE 2. Global T-Cell Lymphoma Market estimates & forecasts by Region 2019-2029 (USD Million)
  • TABLE 3. Global T-Cell Lymphoma Market estimates & forecasts by Lymphoma Type 2019-2029 (USD Million)
  • TABLE 4. Global T-Cell Lymphoma Market estimates & forecasts by Therapy Type 2019-2029 (USD Million)
  • TABLE 5. Global T-Cell Lymphoma Market by segment, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 6. Global T-Cell Lymphoma Market by region, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 7. Global T-Cell Lymphoma Market by segment, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 8. Global T-Cell Lymphoma Market by region, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 9. Global T-Cell Lymphoma Market by segment, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 10. Global T-Cell Lymphoma Market by region, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 11. Global T-Cell Lymphoma Market by segment, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 12. Global T-Cell Lymphoma Market by region, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 13. Global T-Cell Lymphoma Market by segment, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 14. Global T-Cell Lymphoma Market by region, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 15. U.S. T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 16. U.S. T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 17. U.S. T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 18. Canada T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 19. Canada T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 20. Canada T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 21. UK T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 22. UK T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 23. UK T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 24. Germany T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 25. Germany T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 26. Germany T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 27. France T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 28. France T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 29. France T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 30. Italy T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 31. Italy T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 32. Italy T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 33. Spain T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 34. Spain T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 35. Spain T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 36. RoE T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 37. RoE T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 38. RoE T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 39. China T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 40. China T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 41. China T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 42. India T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 43. India T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 44. India T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 45. Japan T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 46. Japan T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 47. Japan T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 48. South Korea T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 49. South Korea T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 50. South Korea T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 51. Australia T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 52. Australia T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 53. Australia T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 54. RoAPAC T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 55. RoAPAC T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 56. RoAPAC T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 57. Brazil T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 58. Brazil T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 59. Brazil T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 60. Mexico T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 61. Mexico T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 62. Mexico T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 63. RoLA T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 64. RoLA T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 65. RoLA T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 66. Row T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 67. Row T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 68. Row T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 69. List of secondary sources, used in the study of global T-Cell Lymphoma Market
  • TABLE 70. List of primary sources, used in the study of global T-Cell Lymphoma Market
  • TABLE 71. Years considered for the study
  • TABLE 72. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global T-Cell Lymphoma Market, research methodology
  • FIG 2. Global T-Cell Lymphoma Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global T-Cell Lymphoma Market, key trends 2021
  • FIG 5. Global T-Cell Lymphoma Market, growth prospects 2022-2029
  • FIG 6. Global T-Cell Lymphoma Market, porters 5 force model
  • FIG 7. Global T-Cell Lymphoma Market, pest analysis
  • FIG 8. Global T-Cell Lymphoma Market, value chain analysis
  • FIG 9. Global T-Cell Lymphoma Market by segment, 2019 & 2029 (USD Million)
  • FIG 10. Global T-Cell Lymphoma Market by segment, 2019 & 2029 (USD Million)
  • FIG 11. Global T-Cell Lymphoma Market by segment, 2019 & 2029 (USD Million)
  • FIG 12. Global T-Cell Lymphoma Market by segment, 2019 & 2029 (USD Million)
  • FIG 13. Global T-Cell Lymphoma Market by segment, 2019 & 2029 (USD Million)
  • FIG 14. Global T-Cell Lymphoma Market, regional snapshot 2019 & 2029
  • FIG 15. North America T-Cell Lymphoma Market 2019 & 2029 (USD Million)
  • FIG 16. Europe T-Cell Lymphoma Market 2019 & 2029 (USD Million)
  • FIG 17. Asia pacific T-Cell Lymphoma Market 2019 & 2029 (USD Million)
  • FIG 18. Latin America T-Cell Lymphoma Market 2019 & 2029 (USD Million)
  • FIG 19. Global T-Cell Lymphoma Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

目次

Global T-Cell Lymphoma Market is valued at approximately USD 1588.89 million in 2021 and is anticipated to grow with a healthy growth rate of more than 8.25% over the forecast period 2022-2029. T-Cell Lymphoma is a type of blood cancer which arises in an immune system named as T-cell. The T-Cell Lymphoma market is expanding because of factors such as rise in lymphoma cancer incidence, advancements in T-cell lymphoma-specific therapies and the risk of lymphoma due to autoimmune disorders. This market is dominated by Johnson & Johnson (Janssen Pharmaceuticals Inc.), Novartis AG, Bristol Myers Squibb Company, Merck & Co. Inc., and F. Hoffmann-La Roche Ltd.

The rising number of blood cancer has increased the prevalence of T-cell lymphoma. As per the Leukemia & Lymphoma Society® (LLS), about one in three people in the United States is diagnosed with leukaemia, lymphoma, or myeloma. In 2021, a total of 186,400 people in the United States are expected to be diagnosed with leukaemia, lymphoma, or myeloma. New cases of leukaemia, lymphoma, and myeloma are expected to account for 9.8% of the estimated 1,898,160 new cancer cases diagnosed in the United States in 2021. Furthermore, the uptake of premium-priced products and immune checkpoint inhibitors as well as the launch of several novel therapies with label extensions of commercialized products are expected to increase the opportunity for this market in the forthcoming years. However, the high cost of Treatment and Adverse Side Effects of Therapies stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global T-Cell Lymphoma Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the dominance of branded products and the region's increasing disease prevalence. According to the Globocan 2020 report, 8,506 cases of non-Hodgkin's lymphoma occurred in Canada in 2020, with 313 deaths. This is expected to increase the incidence of T-cell lymphoma in the country. Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising disease, weak immune systems, rising health awareness among the netizen and active participation of government and nonprofit organizations in the market space.

Major market players included in this report are:

Genmab AS

Johnson & Johnson (Janssen Pharmaceuticals Inc.)

Mundipharma International, Limited

Bristol-Myers Squibb Company

Autolus Therapeutics PLC

Acrotech Biopharma, Inc.

Macopharma

Merck & Co. Inc.

F. Hoffmann-La Roche Ltd

Novartis AG

Recent Developments in the Market:

  • In September 2021, Soligenix Inc. announced that the U.S. Food and Drug Administration's (FDA) Office of Orphan Drug Development granted orphan drug designation to hypericin for the treatment of T-cell lymphoma (CTCL).
  • In December 2020, the FDA approved her new drug application for LB1901. It's an investigational chimeric antigen receptor T-cell therapy for the treatment of adults with relapsed or refractory Cutaneous T-cell lymphoma.
  • In July 2020, miRagen Therapeutics Inc. announced that the Food and Drug Administration (FDA) granted orphan drug designation to cobomarsen for the treatment of her T-cell lymphoma. Cobomarsen is being developed by miRagen in two clinical programs for the treatment of different types of T-cell lymphoma, including a Phase 2 trial in cutaneous T-cell lymphoma (CTCL) and a Phase 1 trial in adult T-cell lymphoma. inhibitor (ATLL) Ultraviolet.

Global T-Cell Lymphoma Market Report Scope:

Historical Data: 2019-2020-2021

Base Year for Estimation: 2021

Forecast period: 2022-2029

Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

Segments Covered: Lymphoma Type, Therapy Type, Region

Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World

Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Lymphoma Type:

Peripheral T-cell Lymphoma

T-cell Lymphoblastic Lymphoma

By Therapy Type:

Radiotherapy

Chemotherapy

Immunotherapy

Stem Cell Transplantation

Other Types of Therapies

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

RoLA

Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Million)
    • 1.2.1. T-Cell Lymphoma Market, by Region, 2019-2029 (USD Million)
    • 1.2.2. T-Cell Lymphoma Market, by Lymphoma Type, 2019-2029 (USD Million)
    • 1.2.3. T-Cell Lymphoma Market, by Therapy Type, 2019-2029 (USD Million)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global T-Cell Lymphoma Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global T-Cell Lymphoma Market Dynamics

  • 3.1. T-Cell Lymphoma Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rise in Lymphoma Cancer Incidence
      • 3.1.1.2. Advancements in T-cell Lymphoma-specific Therapies
      • 3.1.1.3. Risk of Lymphoma due to Autoimmune Disorders
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of Treatment
      • 3.1.2.2. Adverse Side Effects of Therapies
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Uptake Of Premium-Priced Products and Immune Checkpoint Inhibitors
      • 3.1.3.2. Launch Of Several Novel Therapies with Label Extension of Commercialized Products

Chapter 4. Global T-Cell Lymphoma Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global T-Cell Lymphoma Market, by Lymphoma Type

  • 6.1. Market Snapshot
  • 6.2. Global T-Cell Lymphoma Market by Lymphoma Type, Performance - Potential Analysis
  • 6.3. Global T-Cell Lymphoma Market Estimates & Forecasts by Lymphoma Type 2019-2029 (USD Million)
  • 6.4. T-Cell Lymphoma Market, Sub Segment Analysis
    • 6.4.1. Peripheral T-cell Lymphoma
    • 6.4.2. T-cell Lymphoblastic Lymphoma

Chapter 7. Global T-Cell Lymphoma Market, by Therapy Type

  • 7.1. Market Snapshot
  • 7.2. Global T-Cell Lymphoma Market by Therapy Type, Performance - Potential Analysis
  • 7.3. Global T-Cell Lymphoma Market Estimates & Forecasts by Therapy Type 2019-2029 (USD Million)
  • 7.4. T-Cell Lymphoma Market, Sub Segment Analysis
    • 7.4.1. Radiotherapy
    • 7.4.2. Chemotherapy
    • 7.4.3. Immunotherapy
    • 7.4.4. Stem Cell Transplantation
    • 7.4.5. Other Types of Therapies

Chapter 8. Global T-Cell Lymphoma Market, Regional Analysis

  • 8.1. T-Cell Lymphoma Market, Regional Market Snapshot
  • 8.2. North America T-Cell Lymphoma Market
    • 8.2.1. U.S. T-Cell Lymphoma Market
      • 8.2.1.1. Lymphoma Type breakdown estimates & forecasts, 2019-2029
      • 8.2.1.2. Therapy Type breakdown estimates & forecasts, 2019-2029
    • 8.2.2. Canada T-Cell Lymphoma Market
  • 8.3. Europe T-Cell Lymphoma Market Snapshot
    • 8.3.1. U.K. T-Cell Lymphoma Market
    • 8.3.2. Germany T-Cell Lymphoma Market
    • 8.3.3. France T-Cell Lymphoma Market
    • 8.3.4. Spain T-Cell Lymphoma Market
    • 8.3.5. Italy T-Cell Lymphoma Market
    • 8.3.6. Rest of Europe T-Cell Lymphoma Market
  • 8.4. Asia-Pacific T-Cell Lymphoma Market Snapshot
    • 8.4.1. China T-Cell Lymphoma Market
    • 8.4.2. India T-Cell Lymphoma Market
    • 8.4.3. Japan T-Cell Lymphoma Market
    • 8.4.4. Australia T-Cell Lymphoma Market
    • 8.4.5. South Korea T-Cell Lymphoma Market
    • 8.4.6. Rest of Asia Pacific T-Cell Lymphoma Market
  • 8.5. Latin America T-Cell Lymphoma Market Snapshot
    • 8.5.1. Brazil T-Cell Lymphoma Market
    • 8.5.2. Mexico T-Cell Lymphoma Market
    • 8.5.3. Rest of Latin America T-Cell Lymphoma Market
  • 8.6. Rest of The World T-Cell Lymphoma Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
    • 9.2.1. Genmab AS
      • 9.2.1.1. Key Information
      • 9.2.1.2. Overview
      • 9.2.1.3. Financial (Subject to Data Availability)
      • 9.2.1.4. Product Summary
      • 9.2.1.5. Recent Developments
    • 9.2.2. Johnson & Johnson (Janssen Pharmaceuticals Inc.)
    • 9.2.3. Mundipharma International, Limited
    • 9.2.4. Bristol-Myers Squibb Company
    • 9.2.5. Autolus Therapeutics PLC
    • 9.2.6. Acrotech Biopharma, Inc.
    • 9.2.7. Macopharma
    • 9.2.8. Merck & Co. Inc.
    • 9.2.9. F. Hoffmann-La Roche Ltd
    • 9.2.10. Novartis AG

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption